Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy

Philip Hooper; Marie Carole Boucher; Alan Cruess; Keith G. Dawson; Walter Delpero; Mark Greve; Vladimir Kozousek; Wai Ching Lam; David A.L. Maberley

doi:10.1016/j.jcjo.2017.09.027

Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy

Philip Hooper, Marie Carole Boucher, Alan Cruess, Keith G. Dawson, Walter Delpero, Mark Greve, Vladimir Kozousek, Wai Ching Lam, David A.L. Maberley

Résultat de recherche: Article › examen par les pairs

19 Citations (Scopus)

Langue d'origine	English
Pages (de-à)	S45-S74
Journal	Canadian Journal of Ophthalmology
Volume	52
DOI	https://doi.org/10.1016/j.jcjo.2017.09.027
Statut de publication	Published - nov. 2017
Publié à l'externe	Oui

Note bibliographique

Funding Information:
Disclosure: Members of the COS Diabetic Retinopathy Clinical Practice Guideline Expert Committee were volunteers and received no remuneration or honoraria for their time or work. The committee members made the following disclosures regarding their relationships to pharmaceutical and medical device manufacturers in the past 24 months. P.H. received grant/research support from Novartis, honoraria/consulting fees from Novartis, and membership on an advisory panel Novartis, Allergan, and Alcon. M.C.B. received honoraria/consulting fees from Novartis, and is a shareholder in Laboratoires de la Rétine RD. A.C. received grant/research support from Novartis and Pfizer, honoraria/consulting fees from Novartis, membership on an advisory panel/standing committee/board of directors of AMD Alliance Science Panel and Novartis advisory board, and other financial or material interest AREDS 2 (data safety monitoring committee member). K.D. received grant/research support from Merck Frosst Canada Inc., Eli Lilly Canada, GSK, sanofi-aventis, honoraria/consulting fees from Merck Frosst Canada Inc., Eli Lilly Canada, GSK, sanofi-aventis, and membership on an advisory panel/standing committee/board of directors of Merck Frosst Canada Inc., Eli Lilly Canada, GSK, sanofi-aventis, Roche Diagnostics. W.D. has no financial interests or affiliations to declare. M.G. received grant/research support from Novartis, honoraria/consulting fees from Novartis, Bausch & Lomb, Bayer, and is a Director of Secure Diagnostic Imaging Ltd. V.K. received grant/research support from Novartis, Pfizer, Regeneron. W.-C.L. received grant/research support from Allergan and Pfizer, honoraria/consulting fees from Bausch & Lomb, and membership on an advisory panel of Novartis, Allergan. D.M. received honoraria/consulting fees from Allergan, Arctic Dx.

Funding Information:
Support: Funding for the development of this guideline was provided by the Canadian Ophthalmological Society and by the following sponsors (in alphabetical order) in the form of unrestricted educational grants: Alcon Canada Inc., Allergan Canada Inc., AMO, Novartis Canada Inc., Pfizer Canada Inc. Neither industry nor government was involved in the decision to publish guidelines, in the choice of guideline, or in any aspect of guideline development.

ASJC Scopus Subject Areas

Ophthalmology

PubMed: MeSH publication types

Journal Article
Practice Guideline

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.1016/j.jcjo.2017.09.027

Autres fichiers et liens

Citer

@article{cb80d3d7290e4091a1f712660c3b80e6,

title = "Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy",

author = "Philip Hooper and Boucher, {Marie Carole} and Alan Cruess and Dawson, {Keith G.} and Walter Delpero and Mark Greve and Vladimir Kozousek and Lam, {Wai Ching} and Maberley, {David A.L.}",

note = "Funding Information: Disclosure: Members of the COS Diabetic Retinopathy Clinical Practice Guideline Expert Committee were volunteers and received no remuneration or honoraria for their time or work. The committee members made the following disclosures regarding their relationships to pharmaceutical and medical device manufacturers in the past 24 months. P.H. received grant/research support from Novartis, honoraria/consulting fees from Novartis, and membership on an advisory panel Novartis, Allergan, and Alcon. M.C.B. received honoraria/consulting fees from Novartis, and is a shareholder in Laboratoires de la R{\'e}tine RD. A.C. received grant/research support from Novartis and Pfizer, honoraria/consulting fees from Novartis, membership on an advisory panel/standing committee/board of directors of AMD Alliance Science Panel and Novartis advisory board, and other financial or material interest AREDS 2 (data safety monitoring committee member). K.D. received grant/research support from Merck Frosst Canada Inc., Eli Lilly Canada, GSK, sanofi-aventis, honoraria/consulting fees from Merck Frosst Canada Inc., Eli Lilly Canada, GSK, sanofi-aventis, and membership on an advisory panel/standing committee/board of directors of Merck Frosst Canada Inc., Eli Lilly Canada, GSK, sanofi-aventis, Roche Diagnostics. W.D. has no financial interests or affiliations to declare. M.G. received grant/research support from Novartis, honoraria/consulting fees from Novartis, Bausch & Lomb, Bayer, and is a Director of Secure Diagnostic Imaging Ltd. V.K. received grant/research support from Novartis, Pfizer, Regeneron. W.-C.L. received grant/research support from Allergan and Pfizer, honoraria/consulting fees from Bausch & Lomb, and membership on an advisory panel of Novartis, Allergan. D.M. received honoraria/consulting fees from Allergan, Arctic Dx. Funding Information: Support: Funding for the development of this guideline was provided by the Canadian Ophthalmological Society and by the following sponsors (in alphabetical order) in the form of unrestricted educational grants: Alcon Canada Inc., Allergan Canada Inc., AMO, Novartis Canada Inc., Pfizer Canada Inc. Neither industry nor government was involved in the decision to publish guidelines, in the choice of guideline, or in any aspect of guideline development. ",

year = "2017",

month = nov,

doi = "10.1016/j.jcjo.2017.09.027",

language = "English",

volume = "52",

pages = "S45--S74",

journal = "Canadian Journal of Ophthalmology",

issn = "0008-4182",

publisher = "Canadian Ophthalmological Society",

}

TY - JOUR

T1 - Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy

AU - Hooper, Philip

AU - Boucher, Marie Carole

AU - Cruess, Alan

AU - Dawson, Keith G.

AU - Delpero, Walter

AU - Greve, Mark

AU - Kozousek, Vladimir

AU - Lam, Wai Ching

AU - Maberley, David A.L.

N1 - Funding Information: Disclosure: Members of the COS Diabetic Retinopathy Clinical Practice Guideline Expert Committee were volunteers and received no remuneration or honoraria for their time or work. The committee members made the following disclosures regarding their relationships to pharmaceutical and medical device manufacturers in the past 24 months. P.H. received grant/research support from Novartis, honoraria/consulting fees from Novartis, and membership on an advisory panel Novartis, Allergan, and Alcon. M.C.B. received honoraria/consulting fees from Novartis, and is a shareholder in Laboratoires de la Rétine RD. A.C. received grant/research support from Novartis and Pfizer, honoraria/consulting fees from Novartis, membership on an advisory panel/standing committee/board of directors of AMD Alliance Science Panel and Novartis advisory board, and other financial or material interest AREDS 2 (data safety monitoring committee member). K.D. received grant/research support from Merck Frosst Canada Inc., Eli Lilly Canada, GSK, sanofi-aventis, honoraria/consulting fees from Merck Frosst Canada Inc., Eli Lilly Canada, GSK, sanofi-aventis, and membership on an advisory panel/standing committee/board of directors of Merck Frosst Canada Inc., Eli Lilly Canada, GSK, sanofi-aventis, Roche Diagnostics. W.D. has no financial interests or affiliations to declare. M.G. received grant/research support from Novartis, honoraria/consulting fees from Novartis, Bausch & Lomb, Bayer, and is a Director of Secure Diagnostic Imaging Ltd. V.K. received grant/research support from Novartis, Pfizer, Regeneron. W.-C.L. received grant/research support from Allergan and Pfizer, honoraria/consulting fees from Bausch & Lomb, and membership on an advisory panel of Novartis, Allergan. D.M. received honoraria/consulting fees from Allergan, Arctic Dx. Funding Information: Support: Funding for the development of this guideline was provided by the Canadian Ophthalmological Society and by the following sponsors (in alphabetical order) in the form of unrestricted educational grants: Alcon Canada Inc., Allergan Canada Inc., AMO, Novartis Canada Inc., Pfizer Canada Inc. Neither industry nor government was involved in the decision to publish guidelines, in the choice of guideline, or in any aspect of guideline development.

PY - 2017/11

Y1 - 2017/11

UR - http://www.scopus.com/inward/record.url?scp=85032457107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032457107&partnerID=8YFLogxK

U2 - 10.1016/j.jcjo.2017.09.027

DO - 10.1016/j.jcjo.2017.09.027

M3 - Article

C2 - 29074014

AN - SCOPUS:85032457107

SN - 0008-4182

VL - 52

SP - S45-S74

JO - Canadian Journal of Ophthalmology

JF - Canadian Journal of Ophthalmology

ER -